Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association, discusses COVID-19 vaccinations among people with diabetes as they have been disproportionally affected by the pandemic.
Efforts to address COVID-19 in the diabetes community are based, in part, on early recognition that these individuals would be disproportionately impacted, said Robert A. Gabbay, MD, PhD, chief scientific and medical officer at the American Diabetes Association.
Transcript
Is the focus on how much COVID-19 has harmed those with diabetes making an impact? Are people with diabetes getting vaccinated at rates that will make a difference?
There's been a big effort to address COVID-19 in the diabetes community. That, in part, is based on some early recognition that people with diabetes have disproportionately suffered as a result of the pandemic. Whether that's a statistic, like up to 40% of the deaths associated with COVID-19 are people with diabetes, or that people with diabetes are 6 times more likely to be hospitalized, or 12 times more likely to die from COVID-19. So the American Diabetes Association has developed a series of resources for both providers but also, importantly, for people living with diabetes, where they can find out about vaccination, where they can get the latest information, what to do if they get sick, and what are the precautions they can take. The good news is that vaccination rates are rising; we're hoping to have that rise even more. And now we're focused on boosters, because people with diabetes are amongst that high risk group again, that needs to get a booster and so we're encouraging people to do that.
BCI Shows Promise of Personalized Endocrine Therapy in Breast Cancer
January 15th 2025The Breast Cancer Index (BCI) may help identify patients with low-risk breast cancer who could potentially benefit from reduced endocrine therapy, leading to improved quality of life and potentially lower health care costs.
Read More
Managed Care Cast Presents: BTK Inhibitors in Treatment-Naive Patients With CLL and MCL
December 26th 2024A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton tyrosine kinase (BTK) inhibitors, including cost considerations.
Listen
Designing Care for the Underserved Creates Higher-Value Health Solutions
January 12th 2025In the second half of our interview with Brita Roy, MD, MPH, MHS, NYU Grossman School of Medicine, she discusses effective engagement of minoritized populations in discussion of medical mistrust.
Read More
AI's Role in Oncology: Supporting, Not Replacing, Health Care Providers
January 9th 2025In this second half of our interview with Vanderbilt University Medical Center’s Travis Osterman, DO, MS, FAMIA, FASCO, he discusses opportunities for advancing the smart use of artificial intelligence (AI) in cancer care.
Read More